Compare Adaptive Biotechnologies Corp (ADPT) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Virgin Galactic Holdings, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.69 (market cap $4.05B), while Virgin Galactic Holdings, Inc. trades at $3.34 (market cap $488.94M). The key difference: Adaptive Biotechnologies Corp is far larger — about 8.3× Virgin Galactic Holdings, Inc.'s market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | SPCE | |
|---|---|---|
Market Cap | $4.05B | $488.94M |
Sector | Health | Industrials |
52-Week High | $25.45 | $7.52 |
52-Week Low | $12.30 | $2.17 |
Enterprise Value | $4.12B | $588.79M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
SPCE trades at $3.10, up 5.8% in the last session, with a bullish technical signal from moving averages but an overbought RSI. The company continues to post significant losses, with a net income margin of -19,781.3% in 2025, though it has beaten EPS estimates for the last three quarters. Cash flow remains negative, but the trend is improving, with net cash flow narrowing to -$35.17 million in 2025 from -$207 million in 2022. Recent news highlights sector volatility and an upcoming Q2 2026 earnings report on August 12, 2026.
The outlook is highly speculative, with substantial execution risks and cash burn offset by potential in the nascent space tourism market. Analyst consensus is mixed, with 29% buy ratings. Investors face high volatility and operational challenges, making it suitable only for risk-tolerant portfolios seeking long-term growth in a disruptive industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
